[Adverse events related to bevacizumab and the management principles in non-small cell lung cancer].
Cheng
Gang
G
Zhang
Li
L
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D011507:Proteinuria / Q000139:chemically induced; D013923:Thromboembolism / Q000139:chemically induced
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab